These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22110161)

  • 1. Population pharmacokinetics of fingolimod phosphate in healthy participants.
    Wu K; Mercier F; David OJ; Schmouder RL; Looby M
    J Clin Pharmacol; 2012 Jul; 52(7):1054-68. PubMed ID: 22110161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
    Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
    Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
    Kovarik JM; Hartmann S; Bartlett M; Riviere GJ; Neddermann D; Wang Y; Port A; Schmouder RL
    Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
    Ettenger R; Schmouder R; Kovarik JM; Bastien MC; Hoyer PF
    Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
    David OJ; Ocwieja M; Meiser K; Emotte C; Jakab A; Wemer J; den Daas I; Schmouder R
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
    Kovarik JM; Riviere GJ; Neddermann D; Maton S; Hunt TL; Schmouder RL
    J Clin Pharmacol; 2008 Mar; 48(3):303-10. PubMed ID: 18218783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic effects of steady-state fingolimod on antibody response in healthy volunteers: a 4-week, randomized, placebo-controlled, parallel-group, multiple-dose study.
    Boulton C; Meiser K; David OJ; Schmouder R
    J Clin Pharmacol; 2012 Dec; 52(12):1879-90. PubMed ID: 22174429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.
    Tanasescu R; Constantinescu CS
    Expert Opin Drug Metab Toxicol; 2014 Apr; 10(4):621-30. PubMed ID: 24579791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation.
    Snelder N; Ploeger BA; Luttringer O; Stanski DR; Danhof M
    Drug Metab Dispos; 2014 Sep; 42(9):1367-78. PubMed ID: 24965813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral fingolimod (gilenya) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Dec; 52(1353-1354):98-9. PubMed ID: 21344782
    [No Abstract]   [Full Text] [Related]  

  • 14. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in rats after oral and intravenous doses.
    Meno-Tetang GM; Li H; Mis S; Pyszczynski N; Heining P; Lowe P; Jusko WJ
    Drug Metab Dispos; 2006 Sep; 34(9):1480-7. PubMed ID: 16751263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of fingolimod.
    David OJ; Kovarik JM; Schmouder RL
    Clin Pharmacokinet; 2012 Jan; 51(1):15-28. PubMed ID: 22149256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G; Merkely B
    Ideggyogy Sz; 2012 Nov; 65(11-12):369-76. PubMed ID: 23289171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed fingolimod-associated asystole.
    Espinosa PS; Berger JR
    Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.
    Skerjanec A; Tedesco H; Neumayer HH; Cole E; Budde K; Hsu CH; Schmouder R
    J Clin Pharmacol; 2005 Nov; 45(11):1268-78. PubMed ID: 16239360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.